Trial · NCT03036098
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study | From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months) | All Cisplatin-ineligible Randomized Participants - Primary Study | Months | MEDIAN |
| PRIMARY | Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary Study | From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months) | All PD-L1 \>= 1% Randomized Participants - Primary Study | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) in All Randomized Participants for Primary Study | From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months) | All Randomized Participants - Primary Study | Months | MEDIAN |
| SECONDARY | Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-ineligible Randomized Participants for Primary Study | From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months) | All Cisplatin-ineligible Randomized Participants - Primary Study | Months | MEDIAN |
| SECONDARY | Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Participants for Primary Study | From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months) | All PD-L1 \>= 1% Randomized Participants - Primary Study | Months | MEDIAN |
| SECONDARY | Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in All Randomized Participants for Primary Study | From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months) | All Randomized Participants - Primary Study | Months | MEDIAN |
| SECONDARY | Change From Baseline in the European Organization for Research and Treatment of Care Quality-of-Life Questionnaire (EORTC QLQ-C30) Global Health Status Score in All Randomized Participants for Primary Study | At Baseline, Week 4, Week 10, Week 16, Week 20, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 96, Week 108, Week 120, Week 144, Week 156, Week 168, Week 180 and Week 192 | All Randomized Participants - Primary Study | Score on a Scale | MEAN |
| PRIMARY | Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-eligible Participants for Sub-study | From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months) | All Cisplatin-eligible Randomized Participants - Sub-study | Months | MEDIAN |
| PRIMARY | Overall Survival (OS) in Cisplatin-eligible Participants for Sub-study | From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months) | All Cisplatin-eligible Randomized Participants - Sub-study | Months | MEDIAN |
| SECONDARY | Change From Baseline in the European Organization for Research and Treatment of Care Quality-of-Life Questionnaire (EORTC QLQ-C30) Global Health Status Score for Sub-study | At Baseline, Week 4, Week 10, Week 16, Week 20, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 96, Week 108, and Week 120 | All Randomized Participants - Sub-study | Score on a Scale | MEAN |
| SECONDARY | Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] by Programmed Death-Ligand 1 (PD-L1) Expression at ≥1% Expression by Immunohistochemistry (IHC) for Sub-study | From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months) | All PD-L1 \>= 1% Randomized Participants - Sub-study | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] by Programmed Death-Ligand 1 (PD-L1) Expression at ≥1% Expression by Immunohistochemistry (IHC) for Sub-study | From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months) | All PD-L1 \>= 1% Randomized Participants - Sub-study | Months | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03036098/outcomes